| Code | CSB-RA017647MB6HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to Recaticimab, designed for research targeting proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is a secreted serine protease that plays a critical role in cholesterol homeostasis by binding to low-density lipoprotein receptors (LDLRs) on hepatocyte surfaces, promoting their degradation in lysosomes rather than recycling to the cell membrane. By reducing LDLR availability, elevated PCSK9 levels lead to decreased hepatic uptake of LDL cholesterol and consequent hypercholesterolemia. This mechanism has established PCSK9 as a validated therapeutic target in cardiovascular disease, familial hypercholesterolemia, and atherosclerosis research.
Recaticimab represents a fully humanized monoclonal antibody that inhibits PCSK9 function by preventing its interaction with LDLRs, thereby preserving receptor recycling and enhancing LDL clearance from circulation. This biosimilar antibody provides researchers with a valuable tool for investigating PCSK9 biology, lipid metabolism pathways, and cardiovascular disease mechanisms in preclinical studies. It supports exploration of PCSK9 inhibition strategies and related cholesterol regulation research.
There are currently no reviews for this product.